What is Quest Diagnostics's stock-based comp?

Quest Diagnostics (DGX) reported stock-based comp of $20M in Q1 2026.

How has Quest Diagnostics's stock-based comp changed year-over-year?

Quest Diagnostics's stock-based comp decreased by 9.1% year-over-year, from $22M to $20M.

What is the long-term trend for Quest Diagnostics's stock-based comp?

Over 4 years (2021 to 2025), Quest Diagnostics's stock-based comp has grown at a 2.7% compound annual growth rate (CAGR), from $79M to $88M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Quest Diagnostics DGX Stock-Based Comp

Stock-Based Comp at other companies

Myriad GeneticsMYGN

$6.5M-31.6%

Labcorp HoldingsLH

$31.7M-3.4%

Opko HealthOPK

$2.74M+4.5%

NeoGenomicsNEO

$9.64M-10.4%

Exagen Inc.XGN

$655K+57.1%

Personalis, Inc.PSNL

$2.55M+15.1%

Other financials

Income statement

See full

Revenue$2.9B+9.2%

Gross profit$942.0M+9.2%

Operating income$399.0M+15.3%

Net income$252.0M+14.5%

EPS (diluted)$2.24+15.5%

Balance sheet

See full

Cash & equivalents$393.0M+109%

Total debt$6.4B-2.5%

Total equity$7.4B+6.3%

Total assets$16.7B+5.5%

Cash flow

See full

Operating cash flow$278.0M-11.5%

CapEx$114.0M-2.6%

Free cash flow$164.0M-16.8%

Valuation

See full

Market cap$23.03B+18.6%

Enterprise value$29.04B+14.0%

P/E22.5×+2.0×

P/S2×+0.2×

Profitability

See full

Gross margin33.2%+0.4pp

Operating margin14.3%+0.6pp

Net margin9.1%+0.2pp

FCF margin11.8%+1.4pp

Returns & leverage

See full

Return on equity14.3%+0.9pp

Debt / equity0.9×-0.1×

Current ratio1.2×-0.3×

Where this comes from

Reported directly by Quest Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Quest Diagnostics’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quest Diagnostics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Quest Diagnostics's stock-based comp?: Quest Diagnostics (DGX) reported stock-based comp of $20M in Q1 2026.
How has Quest Diagnostics's stock-based comp changed year-over-year?: Quest Diagnostics's stock-based comp decreased by 9.1% year-over-year, from $22M to $20M.
What is the long-term trend for Quest Diagnostics's stock-based comp?: Over 4 years (2021 to 2025), Quest Diagnostics's stock-based comp has grown at a 2.7% compound annual growth rate (CAGR), from $79M to $88M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.